American Association for Cancer Research

April 1–5, 2017 | Walter E. Washington Convention Center, Washington, D.C.

Event

Empowering the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured.

At Fluidigm, we are focused on providing trusted research solutions to help you interrogate the tumor microenvironment, blood-based cancers and immune cell function with unprecedented resolution. Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough. Together we will transform the future of cancer care.

Visit Fluidigm at Booth 2417

Exhibit Dates & Hours:

  • Sunday, April 2: 1:00–5:00 pm
  • Monday, April 3: 9:00 am–5:00 pm
  • Tuesday, April 4: 9:00 am–5:00 pm
  • Wednesday, April 5: 9:00 am–12:00 pm

Product Presentations

Deeply profile the tumor immune response from every angle.

Helios™, a CyTOF® System

Deeply profile immune cell subpopulations and identify signatures of checkpoint response using mass cytometry.

 Helios

Biomark™ HD

Reveal the molecular signatures of tumor immune response using a 170-target gene expression qPCR assay on the Biomark HD.

 Biomark HD

Juno™

Achieve greater scalability and cost efficiency in NGS library preparation.

 Juno

C1™

Find the missing link between T cell response and clonality with single-cell TCR sequencing on the C1 system.

 Juno

2017 AACR Posters Featuring Fluidigm Technology & Presentations of Interest


Mass Cytometry

Saturday, April 1

Time

Title

Presenting Author & Institution

Session

Location or Poster

1:30 pm Interrogating immune environment within tumor tissue Dhodapkar, K.
Yale University
MW11 Ballroom C, Level 3
2:00 pm Using CyTOF to measure global immune competence Maecker, H.T.
Stanford
MW11 Ballroom C, Level 3
1:00–5:00 pm Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade Wei, S.C.
UT MD Anderson Cancer Center
PO.IM02.02 592/26

Sunday, April 2

Time

Title

Presenting Author & Institution

Session

Location or Poster

1:00–5:00 pm

Mass cytometry of human glioblastoma characterizes more than 99 percent of cells and reveals intratumoral cell subsets defined by contrasting signaling network profiles

Leelatian, N.
Vanderbilt University

PO.MCB01.02

364/20

4:35 pm

Phenotypic analysis of single-cell breast cancer inhibition data reveals insights into EMT Cheng, W.S.
Yale University

MS.BSB01.01

977

Monday, April 3

Time

Title

Presenting Author & Institution

Session

Location or Poster

1:00–5:00 pm

Single cell mass cytometry analysis of human lung adenocarcinoma

Doxie, D.B.
Vanderbilt University
PO.TB11.01 2911/7
1:00-5:00 pm Characterizing human melanoma treatment response in vivo using single-cell mass cytometry analysis of longitudinal tumor biopsies Doxie, D.B.
Vanderbilt University
PO.TB11.01 2920/16
1:00-5:00 pm MYC functions as a master switch for natural killer cell-mediated immune surveillance of lymphoid malignancies Swaminathan, S.
Stanford
PO.TB06.03 2943/14

Tuesday, April 4

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma

Qazi, M.
McMaster University

PO.IM02.05

3639/12

8:00 am-12:00 pm

INCB52793 JAK1 inhibitor synergizes with ATRA to inhibit expansion of AML

Ramsey, H.E.
Vanderbilt University

PO.CL01.04

3726/11

8:00 am-12:00 pm

Dissecting small cell lung carcinoma heterogeneity and chemotherapy resistance with mass cytometry

Lehman, J.M.
Vanderbilt University

PO.TB11.02

3935/2

4:05 pm

Single cell signaling analysis reveals circulating tumor cell markers of drug susceptibility and tumor heterogeneity

Karabacak, N.M.
Massachusetts General Hospital      

MS.CL10.02

Rm 146, Level 1

1:00-5:00 pm

Targetable nodes in fibroblast-supported melanoma cells that show resistance to BRAF inhibitors

Seip, K.
Oslo University Hospital

PO.MCB01.07

4329/8

Wednesday, April 5

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Saenz, D.T.
MD Anderson Cancer Center

PO.ET06.04

5067/12


Imaging Mass Cytometry

Saturday, April 1

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:30 am Next-generation pathology: Quantitative immunofluorescence and imaging mass cytometry Schalper, K.A.
Yale University    

MW10 Ballroom C, Level 3

Monday, April 3

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

Multiplexed analysis of fixed tumor tissues using imaging mass cytometry

Villarroel-Espindola, F.
Yale University
PO.IM02.08 1635/13
1:00-5:00 pm In vitro drug effects on cancer cell morphology and functional state revealed by multiparameter imaging mass cytometry Ornatsky, O.
Fluidigm Canada
PO.ET02.03 2014/01

Single-Cell Genomics

Sunday, April 2

Time

Title

Presenting Author & Institution

Session

Location or Poster

1:00-5:00 pm Acquisition of temozolomide resistance: Identification of a new drug tolerant stage in glioblastoma cells Rabé, M. 
Université de Nantes, INSERM
PO.ET04.04 92/13
1:00-5:00 pm Single cell mRNA expression profiling reveals heterogeneity of normal and malignant breast stem cell populations Fouladdel, S.    
University of Michigan
PO.TB02.01 939/27
1:00–5:00 pm Altering intratumoral heterogeneity in HER2+ breast cancers with PTEN inactivation and trastuzumab therapy Burnett, J.P.
University of Michigan
PO.IM02.01 940/28

Monday, April 3

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

Single-cell transcriptomics reveals differential DNA repair signatures after chemotherapy in high-grade serous ovarian cancer

Farkkila, A.
UniversityofHelsinki

PO.MCB07.02

1428/27

8:00 am–12:00 pm

Evaluating the metastatic potential and the molecular heterogeneity of patient-derived orthotopic xenograft models of triple-negative breast cancer Ramani, V.C.
Stanford

PO.TB01.02

18/47/21

8:00 am–12:00 pm

Single-cell analysis of transcription factors provides deeper characterization of cancer cells

Egidio, C.
Fluidigm

LBPO.MCB02

LB-076

8:00 am–12:00 pm

Improved single-cell mRNA sequencing for transcriptome and paired-chain TCR analysis of primary human CD3+ T cells Egidio, C.
Fluidigm

LBPO.MCB02

LB-078

1:00–5:00 pm

Label-free enrichment and integrated full-length mRNA transcriptome analysis of single live circulating tumor cells from breast cancer patients

Ramalingam, N.
Fluidigm

 

2923/19

Tuesday, April 4

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

Transcriptome differences in tyrosine kinase inhibitor-resistant clones of EGFR-mutant lung cancer using a new microfluidic assay for concurrent single-cell RNA and targeted DNA sequencing

Kong, S.L.
Genome Institute of Singapore
PO.ET04.01 3153/13
1:00-5:00 pm

Single-cell protein-mRNA co-detection to reveals subpopulation-specific correlation patterns

Gong, H.
Fluidigm
PO.MCB04.04 4497/30

Wednesday, April 5

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

Single cell sequencing of high grade serous ovarian cancer

Starr, T.K.
University of Minnesota

PO.MCB09.08

5402/13


Genomics

Monday, April 3

Time

Title

Presenting Author & Institution

Session

Location or Poster

1:00–5:00 pm Comparison of blood based liquid biopsy methodologies for improved risk assessment of prostate cancer (PCa) Rajpurohit, Y.
Janssen R&D
PO.CL10.07 2755/25

Tuesday, April 4

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

Comprehensive characterization of genomic and transcriptomic heterogeneity in advanced bladder cancer by multiregional analysis

Thomsen, M.B.H.
Aarhus University Hospital

PO.TB11.02

3948/15

1:00–5:00 pm

Inherited mutations in BRCA1 and BRCA2 in an unselected multi-ethnic cohort of Asian breast cancer patients and healthy controls from Malaysia Wen, W.X.
Cancer Research Malaysia

PO.EP01.06

4288/24

1:00–5:00 pm

mtDNA sequencing in HNSCC as a measurer of intratumoral heterogeneity and lymph node metastasis

Schubert, A.D.
John Hopkins University

PO.CL10.02

4667/28

Wedneday, April 5

Time

Title

Presenting Author & Institution

Session

Location or Poster

8:00 am–12:00 pm

An evaluation of DNA and RNA based blood biomarkers in prostate cancer

Antonello, J.
CRUK Manchester
PO.CL10.09 5685/9
8:00 am–12:00 pm HOXA4 and HOXB3 gene expression signature as a biomarker of tumor recurrence in patients with high-grade serous ovarian cancer (HGSOC) following primary cytoreductive surgery and first-line adjuvant chemotherapy Patel, J.N.
Levine Cancer Institute
PO.CL10.10 5708/2

Social Media

Can’t make it to all of the sessions? Follow @fluidigm with #AACR17 and like us on Facebook for scientific and event updates.